C-Q4XZSensei Biotherapeutics
oncology, PAM pathway inhibition, oral multi-node therapy
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Q4XZ
C-Q4XZC-Q4XZoncology, PAM pathway inhibition, oral multi-node therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Sensei Biotherapeutics oncology, PAM pathway inhibition, oral multi-node therapy
Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway, described on the site as the most frequently altered oncogenic pathway in cancer. Its lead candidate, PIKTOR, is an all-oral combination designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously. The site lists programs in endometrial cancer, breast cancer (HR+/HER2-), and potential future indications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Sensei Biotherapeutics — Translational · Bottom quartile. Derived deterministically from 7 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic